You are here: Industry Insights > SARS-CoV-2

News List

Lilly Provides Update on SARS-CoV-2 Neutralizing Antibody Programs americanpharmaceuticalreview
October 14, 2020
Eli Lilly and Company announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies ...
The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies americanpharmaceuticalreview
October 14, 2020
The Native Antigen Company has announced the introduction of ten new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19.
FDA broadly supports Oragenics’ Pre-IND development programme for SARS-CoV-2 vaccine pharmaceutical-business-review
October 10, 2020
Oragenics, Inc. announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine ...
Eisai Enters Joint Development Agreement for COVID-19 Therapeutics contractpharma
October 10, 2020
Aims to understand the mechanism of COVID-19 aggravation based on SARS-CoV-2 infection and to create drugs that prevent the aggravation of COVID-19.
Moleculin Announces Antiviral Drug Candidates Demonstrate In Vitro Activity against HIV americanpharmaceuticalreview
October 10, 2020
Moleculin Biotech announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing in vitro activity in a range of infectious diseases.
Cepheid Receives EUA for SARS-CoV-2, Flu A, Flu B and RSV Combination Test americanpharmaceuticalreview
October 09, 2020
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19 ...
SARS-CoV-2 RT-PCR Test v2.0 Granted Authorized for Emergency Use in US americanpharmaceuticalreview
September 30, 2020
Vela Diagnostics announced the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 has obtained the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
Scientists trace severe COVID-19 to faulty genes and an autoimmune condition worldpharmanews
September 27, 2020
More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation.
CEBINA Reports Positive Findings on Azelastine Potency for COVID-19 americanpharmaceuticalreview
September 27, 2020
CEBINA GmbH has announced further positive results in its collaborative COVID-19 drug repurposing project, demonstrating allergy nasal spray medication containing azelastine has potent efficacy against SARS-CoV-2 in a human 3D nasal tissue model.
Herd immunity is an impractical COVID-19 mitigation strategy, says study europeanpharmaceuticalreview
September 27, 2020
Researchers who designed a transmission model for COVID-19 demonstrated that attempting to establish herd immunity against COVID-19 would be too challenging.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page